Prognostic value of baseline genetic features and newly identified TP53 mutations in advanced breast cancer
Sign Up to like & getrecommendations! Published in 2022 at "Molecular Oncology"
DOI: 10.1002/1878-0261.13297
Abstract: Approximately 30% of breast cancer (BC) patients suffer from disease relapse after definitive treatment. Monitoring BC at baseline and disease progression using comprehensive genomic profiling would facilitate the prediction of prognosis. We retrospectively studied 101… read more here.
Keywords: baseline; tp53 mutations; advanced breast; breast cancer ... See more keywords
The spectrum of subclonal TP53 mutations in chronic lymphocytic leukemia: A next generation sequencing retrospective study
Sign Up to like & getrecommendations! Published in 2022 at "Hematological Oncology"
DOI: 10.1002/hon.3063
Abstract: Chronic lymphocytic leukemia (CLL) is a hematological disorder with complex clinical and biological behavior. TP53 mutational status and cytogenetic assessment of the deletion of the corresponding locus (17p13.1) are considered the most relevant biomarkers associated… read more here.
Keywords: lymphocytic leukemia; subclonal tp53; tp53 mutations; tp53 ... See more keywords
TP53 mutation and survival in aggressive B cell lymphoma
Sign Up to like & getrecommendations! Published in 2017 at "International Journal of Cancer"
DOI: 10.1002/ijc.30838
Abstract: TP53 is mutated in 20–25% of aggressive B‐cell lymphoma (B‐NHL). To date, no studies have addressed the impact of TP53 mutations in prospective clinical trial cohorts. To evaluate the impact of TP53 mutation to current… read more here.
Keywords: tp53 mutation; aggressive cell; tp53; tp53 mutations ... See more keywords
Radiomics Strategy for Molecular Subtype Stratification of Lower‐Grade Glioma: Detecting IDH and TP53 Mutations Based on Multimodal MRI
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Magnetic Resonance Imaging"
DOI: 10.1002/jmri.25960
Abstract: Noninvasive detection of isocitrate dehydrogenase (IDH) and TP53 mutations are meaningful for molecular stratification of lower‐grade gliomas (LrGG). read more here.
Keywords: stratification lower; idh tp53; tp53 mutations; lower grade ... See more keywords
TP53 mutations in head and neck cancer
Sign Up to like & getrecommendations! Published in 2022 at "Molecular Carcinogenesis"
DOI: 10.1002/mc.23385
Abstract: Head and neck squamous cell carcinomas (HNSCCs) arising in the mucosal linings of the upper aerodigestive tract are highly heterogeneous, aggressive, and multifactorial tumors affecting more than half a million patients worldwide each year. Classical… read more here.
Keywords: mutations head; neck cancer; head neck; tp53 mutations ... See more keywords
Prognostic and therapeutic stratification in CLL: focus on 17p deletion and p53 mutation
Sign Up to like & getrecommendations! Published in 2018 at "Annals of Hematology"
DOI: 10.1007/s00277-018-3503-6
Abstract: Chronic lymphocytic leukemia (CLL), a disorder for which B cell heterogeneity and increased cellular proliferation play central pathogenic roles, displays several genetic abnormalities that are associated with poor prognosis and have therapeutic implications. In this… read more here.
Keywords: cll; tp53 mutations; 17p deletion; mutation ... See more keywords
Chromothripsis in myeloid malignancies
Sign Up to like & getrecommendations! Published in 2024 at "Annals of Hematology"
DOI: 10.1007/s00277-024-05814-9
Abstract: Chromothripsis refers to massive genomic rearrangements developed during a catastrophic event. In total acute myeloid leukemia (AML), the incidence of chromothripsis ranges from 0 to 6.6%, in cases of complex karyotype AML, the incidence of… read more here.
Keywords: tp53 mutations; chromothripsis myeloid; chromothripsis typically; incidence chromothripsis ... See more keywords
Aberrant p53 immunostaining patterns in breast carcinoma of no special type strongly correlate with presence and type of TP53 mutations
Sign Up to like & getrecommendations! Published in 2024 at "Virchows Archiv"
DOI: 10.1007/s00428-024-03897-3
Abstract: Recent studies have revealed an association between TP53 mutations and endocrine resistance in hormone receptor-positive, HER2-negative breast cancer (HR + HER2 −BC). Aberrant p53 immunostaining (IHC) patterns may provide a surrogate marker for TP53 mutations. Building upon… read more here.
Keywords: tp53 mutations; p53 immunostaining; type; aberrant p53 ... See more keywords
Prevalence and timing of TP53 mutations in del(17p) myeloma and effect on survival
Sign Up to like & getrecommendations! Published in 2017 at "Blood Cancer Journal"
DOI: 10.1038/bcj.2017.76
Abstract: The recent remarkable advances in multiple myeloma (MM) therapy and outcomes have had mixed impact on patients with adverse risk genetics, many of whom continue to have inferior outcomes. This applies particularly to deletion of… read more here.
Keywords: del 17p; timing tp53; prevalence timing; tp53 mutations ... See more keywords
The differential diagnosis of a TP53 genetic testing result
Sign Up to like & getrecommendations! Published in 2018 at "Genetics in Medicine"
DOI: 10.1038/gim.2017.250
Abstract: The Li-Fraumeni cancer predisposition syndrome (LFS, MIM 151623) was originally described as an autosomal dominantly inherited syndrome characterized by childhood sarcomas and multiple other cancer types and is often due to germ-line mutations in the… read more here.
Keywords: germ line; genetic testing; cancer; tp53 mutations ... See more keywords
The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases
Sign Up to like & getrecommendations! Published in 2017 at "Leukemia"
DOI: 10.1038/leu.2016.263
Abstract: Alterations in TP53 have been described in many cancer types including hematological neoplasms. We aimed at comparing TP53 mutations (mut) and deletions (del) in a large cohort of patients with hematological malignancies (n=3307), including AML… read more here.
Keywords: cll; mut del; 3307 cases; tp53 mutations ... See more keywords